<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833816</url>
  </required_header>
  <id_info>
    <org_study_id>2019-48</org_study_id>
    <secondary_id>2020-004812-81</secondary_id>
    <nct_id>NCT04833816</nct_id>
  </id_info>
  <brief_title>Ketamine Low dOse Evaluation on Morphine Consumption in Traumatic Patient</brief_title>
  <acronym>KLOE</acronym>
  <official_title>Ketamine Low dOse Evaluation on Morphine Consumption in Traumatic Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate a significant reduction of at least 25% in opioid&#xD;
      consumption at 48 hours of management of severe trauma, while demonstrating non-inferiority&#xD;
      in terms of analgesia, in a group of patients receiving a continuous infusion of low dose&#xD;
      ketamine compared to a placebo group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total dose of sufentanil</measure>
    <time_frame>48 hours</time_frame>
    <description>All doses of sufentanil and opiods administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total amount of opiods</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium</measure>
    <time_frame>5 days</time_frame>
    <description>Scale CAM-ICU (confusion assesment method)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>SF-36 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronical pain</measure>
    <time_frame>3 months</time_frame>
    <description>SF-MPQ-2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Traumatic Injury</condition>
  <arm_group>
    <arm_group_label>Ketamin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will get a bolus of ketamine at 0.1 mg / kg followed by a continuous infusion of ketamine at a dose of 0.15 mg / kg / hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will get a bolus of NaCL at 0.1 mg / kg followed by a continuous infusion of NaCl at a dose of 0.15 mg / kg / hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of drug</intervention_name>
    <description>Administration of ketamin during the 48h after trauma</description>
    <arm_group_label>Ketamin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adult&#xD;
&#xD;
          -  Trauma patient presenting at least 2 lesions in two different regions as defined by&#xD;
             the ISS (injury severity score) (Head or neck, Face, Thorax, Abdomen and pelvic&#xD;
             contents, Upper limbs or pelvic girdle, Lower limbs, External (any skin surface).&#xD;
&#xD;
          -  Patient presenting at least two regional disorders classified as moderate to maximum&#xD;
             defined by an AIS (Abbreviated Injury Scale)&gt; 1.&#xD;
&#xD;
          -  Patient having signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with an indication for deep sedation (intracranial hypertension or acute&#xD;
             respiratory distress syndrome).&#xD;
&#xD;
          -  Patient in whom the infusion could not be started within the first 6 hours of initial&#xD;
             treatment.&#xD;
&#xD;
          -  Patient whose state of consciousness is incompatible with understanding the protocol.&#xD;
&#xD;
          -  Patient with chronic unbalanced arterial hypertension.&#xD;
&#xD;
          -  Patient with severe heart failure.&#xD;
&#xD;
          -  Patient with a BMI&gt; 35 kg / m² or a weight of more than 120 kg.&#xD;
&#xD;
          -  Patient with chronic analgesic consumption defined by consumption of opioid&#xD;
             derivatives for more than a week for an intercurrent illness.&#xD;
&#xD;
          -  Presence of a history of chronic pain.&#xD;
&#xD;
          -  Presence of a history of epilepsy.&#xD;
&#xD;
          -  Presence of a history of psychosis or drug addiction.&#xD;
&#xD;
          -  Presence of a history of stroke.&#xD;
&#xD;
          -  Patients with an allergy to the molecule or excipients composing ketamine&#xD;
&#xD;
          -  Patients with an allergy to the molecule or to the excipients making up sufentanil or&#xD;
             paracetamol.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman.&#xD;
&#xD;
          -  Patient not understanding French.&#xD;
&#xD;
          -  Protected adult patient (under guardianship, curatorship or legal protection).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>AP-HM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Duclos, MD</last_name>
    <phone>0491965531</phone>
    <phone_ext>33</phone_ext>
    <email>gary.duclos@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service Anesthésie Réanimation - Hôpital nord</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gary Duclos</last_name>
      <phone>0491965531</phone>
      <email>gary.duclos@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ketamine</keyword>
  <keyword>analgesia</keyword>
  <keyword>ISS</keyword>
  <keyword>trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

